Single Dose Anti-IL-23 Antibody SCH 900222 versus Placebo in Subjects with Crohn's Disease.

Trial Profile

Single Dose Anti-IL-23 Antibody SCH 900222 versus Placebo in Subjects with Crohn's Disease.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2010

At a glance

  • Drugs Tildrakizumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 12 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top